Trial Profile
A Phase 1 Study in Healthy Subjects to Evaluate the Relative Bioavailability of Two Lutikizumab Formulations and to Evaluate Lutikizumab Pharmacokinetics, Safety, and Tolerability in Healthy Chinese Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Mar 2024
Price :
$35
*
At a glance
- Drugs Lutikizumab (Primary)
- Indications Hidradenitis suppurativa; Osteoarthritis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 12 Mar 2024 Status changed from active, no longer recruiting to completed.
- 14 Dec 2023 Status changed from recruiting to active, no longer recruiting.
- 04 Oct 2023 Status changed from completed to recruiting.